404 related articles for article (PubMed ID: 38139341)
1. Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD).
Zhao Y; Zhou Y; Wang D; Huang Z; Xiao X; Zheng Q; Li S; Long D; Feng L
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139341
[TBL] [Abstract][Full Text] [Related]
2. Endoplasmic reticulum stress in nonalcoholic (metabolic associated) fatty liver disease (NAFLD/MAFLD).
Flessa CM; Kyrou I; Nasiri-Ansari N; Kaltsas G; Kassi E; Randeva HS
J Cell Biochem; 2022 Oct; 123(10):1585-1606. PubMed ID: 35490371
[TBL] [Abstract][Full Text] [Related]
3. Abnormal metabolism in hepatic stellate cells: Pandora's box of MAFLD related hepatocellular carcinoma.
Sun YD; Zhang H; Li YM; Han JJ
Biochim Biophys Acta Rev Cancer; 2024 Mar; 1879(2):189086. PubMed ID: 38342420
[TBL] [Abstract][Full Text] [Related]
4. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study.
Johira Y; Nakahara T; Kinami T; Yamasaki S; Kosaka M; Shirane Y; Miura R; Murakami S; Yano S; Amioka K; Naruto K; Ando Y; Kosaka Y; Kodama K; Uchikawa S; Fujino H; Ono A; Murakami E; Okamoto W; Yamauchi M; Kawaoka T; Hayes CN; Tsuge M; Imamura M; Aikata H; Oka S
BMC Gastroenterol; 2023 Jun; 23(1):222. PubMed ID: 37380950
[TBL] [Abstract][Full Text] [Related]
5. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.
Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liao SH; Hong CM; Liu CH; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
Hepatol Int; 2023 Oct; 17(5):1139-1149. PubMed ID: 37247045
[TBL] [Abstract][Full Text] [Related]
6. The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study.
Chen YG; Yang CW; Chung CH; Ho CL; Chen WL; Chien WC
Hepatol Int; 2022 Aug; 16(4):807-816. PubMed ID: 35064545
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease.
Ramanathan R; Ali AH; Ibdah JA
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806284
[TBL] [Abstract][Full Text] [Related]
8. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
Guerreiro GTS; Longo L; Fonseca MA; de Souza VEG; Álvares-da-Silva MR
Hepatol Int; 2021 Apr; 15(2):380-391. PubMed ID: 33694066
[TBL] [Abstract][Full Text] [Related]
9. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease.
Lim S; Kim JW; Targher G
Trends Endocrinol Metab; 2021 Jul; 32(7):500-514. PubMed ID: 33975804
[TBL] [Abstract][Full Text] [Related]
10. Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma.
Song BG; Choi SC; Goh MJ; Kang W; Sinn DH; Gwak GY; Paik YH; Choi MS; Lee JH; Paik SW
JHEP Rep; 2023 Sep; 5(9):100810. PubMed ID: 37538246
[TBL] [Abstract][Full Text] [Related]
11. Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis.
Yao N; Yang Y; Li X; Wang Y; Guo R; Wang X; Li J; Xie Z; Li B; Cui W
Front Nutr; 2022; 9():906511. PubMed ID: 35782947
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome.
Sinn DH; Kang D; Choi SC; Hong YS; Zhao D; Guallar E; Park Y; Cho J; Gwak GY
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1873-1880.e1. PubMed ID: 36152895
[TBL] [Abstract][Full Text] [Related]
14. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Kang SH; Cho Y; Jeong SW; Kim SU; Lee JW;
Clin Mol Hepatol; 2021 Apr; 27(2):257-269. PubMed ID: 33751877
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease.
Khanmohammadi S; Kuchay MS
Pharmacol Res; 2022 Nov; 185():106507. PubMed ID: 36252773
[TBL] [Abstract][Full Text] [Related]
16. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD).
Méndez-Sánchez N; Díaz-Orozco LE
Med Sci Monit; 2021 Jul; 27():e933860. PubMed ID: 34248137
[TBL] [Abstract][Full Text] [Related]
17. Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies.
Habibullah M; Jemmieh K; Ouda A; Haider MZ; Malki MI; Elzouki AN
Front Med (Lausanne); 2024; 11():1291501. PubMed ID: 38323033
[TBL] [Abstract][Full Text] [Related]
18. Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD).
Subramanian P; Hampe J; Tacke F; Chavakis T
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805998
[TBL] [Abstract][Full Text] [Related]
19. The Gut Microbiome and Ferroptosis in MAFLD.
Ji J; Wu L; Wei J; Wu J; Guo C
J Clin Transl Hepatol; 2023 Feb; 11(1):174-187. PubMed ID: 36406312
[TBL] [Abstract][Full Text] [Related]
20. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC.
Conci S; Cipriani F; Donadon M; Marchitelli I; Ardito F; Famularo S; Perri P; Iaria M; Ansaloni L; Zanello M; La Barba G; Patauner S; Pinotti E; Molfino S; Germani P; Romano M; Sciannamea I; Ferrari C; Manzoni A; Troci A; Fumagalli L; Delvecchio A; Floridi A; Memeo R; Chiarelli M; Crespi M; Zimmitti G; Griseri G; Antonucci A; Zanus G; Tarchi P; Baiocchi GL; Zago M; Frena A; Ercolani G; Jovine E; Maestri M; Valle RD; Grazi GL; Romano F; Giuliante F; Torzilli G; Aldrighetti L; Ruzzenente A;
Eur J Surg Oncol; 2022 Jan; 48(1):103-112. PubMed ID: 34325939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
